AI Engines For more Details: Perplexity Kagi Labs You
Psychotic Disorders: Chlorprothixene hydrochloride is primarily used in the treatment of psychotic disorders such as schizophrenia. It helps alleviate symptoms such as hallucinations (seeing or hearing things that are not there), delusions (false beliefs), disorganized thinking, and agitation. Chlorprothixene works by blocking dopamine receptors in the brain, which are believed to be involved in the pathophysiology of psychotic disorders. By antagonizing dopamine receptors, chlorprothixene helps restore the balance of neurotransmitters in the brain, reducing the severity of psychotic symptoms.
Bipolar Disorder: Chlorprothixene hydrochloride may also be used in the management of bipolar disorder, particularly during manic episodes characterized by elevated mood, increased energy, and impulsivity. It can help stabilize mood and reduce agitation and aggression in individuals experiencing acute manic episodes. Chlorprothixene may be used alone or in combination with mood stabilizers or other antipsychotic medications to manage bipolar disorder effectively.
Agitation and Aggression: Chlorprothixene hydrochloride may be prescribed to manage agitation and aggression in various psychiatric conditions, including schizophrenia, bipolar disorder, and dementia. It helps calm and sedate individuals who are experiencing severe agitation or aggressive behavior, thereby reducing the risk of harm to themselves or others. Chlorprothixene's sedative properties may also be beneficial in the short-term management of acute behavioral disturbances in psychiatric emergencies.
Anxiety Disorders: In some cases, chlorprothixene hydrochloride may be used off-label in the treatment of anxiety disorders, particularly when anxiety symptoms are severe and refractory to other treatments. It can help reduce anxiety and tension by exerting sedative and anxiolytic effects. However, chlorprothixene is generally not considered a first-line treatment for anxiety disorders due to the risk of side effects and the availability of safer alternatives.
Side Effects: Common side effects of chlorprothixene hydrochloride may include drowsiness, dizziness, blurred vision, dry mouth, constipation, urinary retention, orthostatic hypotension (low blood pressure upon standing), and weight gain. It may also cause extrapyramidal symptoms such as tremors, rigidity, akathisia (restlessness), and tardive dyskinesia (involuntary movements). Rare but serious side effects may include neuroleptic malignant syndrome (NMS), a potentially life-threatening condition characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction.
Contraindications: Chlorprothixene hydrochloride is contraindicated in individuals with known hypersensitivity to the medication or any of its components, as well as those with severe central nervous system depression, coma, or blood dyscrasias. It should be used with caution in elderly patients, those with cardiovascular disease, epilepsy, or liver impairment, and pregnant or breastfeeding women. Chlorprothixene may interact with other medications, including central nervous system depressants, anticholinergic agents, and certain antidepressants, so it is important to inform the healthcare provider of all medications being taken.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 5.3 | 0.9 | 4.89 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.5 | 2.4 | 0.46 |
| Allergies | 7.9 | 4.3 | 0.84 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7 | 7.7 | -0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.2 | 2.58 |
| Ankylosing spondylitis | 5 | 1.9 | 1.63 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.8 | 0.3 | 5 |
| Asthma | 6.2 | 3.2 | 0.94 |
| Atherosclerosis | 2.3 | 3 | -0.3 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11 | 11.4 | -0.04 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.7 | 1.7 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.9 | 2.6 | -1.89 |
| Carcinoma | 4.5 | 2.6 | 0.73 |
| Celiac Disease | 3.2 | 4.3 | -0.34 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 5.9 | 7.7 | -0.31 |
| Chronic Kidney Disease | 4.7 | 2.8 | 0.68 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2 | 2 | 0 |
| Chronic Urticaria (Hives) | 1.6 | 1.8 | -0.13 |
| Coagulation / Micro clot triggering bacteria | 1.6 | 1.3 | 0.23 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 7.8 | 2.5 | 2.12 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.7 | 3 | -0.11 |
| COVID-19 | 11.1 | 14.2 | -0.28 |
| Crohn's Disease | 9.7 | 6.9 | 0.41 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.9 | 1.7 | -0.89 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 3.4 | 1.4 | 1.43 |
| Denture Wearers Oral Shifts | 1.6 | 1.6 | |
| Depression | 12 | 11 | 0.09 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.4 | 2.4 | 0 |
| Endometriosis | 3.2 | 2.3 | 0.39 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.1 | 2.8 | 0.46 |
| erectile dysfunction | 2.2 | 0.3 | 6.33 |
| Fibromyalgia | 3.2 | 2.6 | 0.23 |
| Functional constipation / chronic idiopathic constipation | 6.5 | 4.3 | 0.51 |
| gallstone disease (gsd) | 4.1 | 1.6 | 1.56 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.9 | 1.2 | 0.58 |
| Generalized anxiety disorder | 3.6 | 3 | 0.2 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.3 | 1.3 | 0.77 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.3 | 0.3 | 3.33 |
| Hashimoto's thyroiditis | 3.8 | 1.7 | 1.24 |
| Heart Failure | 4.7 | 2.4 | 0.96 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.6 | 0.6 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.8 | 0.6 | 0.33 |
| hyperglycemia | 2.7 | 2.2 | 0.23 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.2 | 6.7 | -0.29 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.8 | 0.9 | 3.22 |
| IgA nephropathy (IgAN) | 1.9 | 5.6 | -1.95 |
| Inflammatory Bowel Disease | 10.4 | 11.4 | -0.1 |
| Insomnia | 2.5 | 3.5 | -0.4 |
| Intelligence | 1.7 | 0.6 | 1.83 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 8.7 | 6.4 | 0.36 |
| ischemic stroke | 3.4 | 1.7 | 1 |
| Liver Cirrhosis | 8.8 | 5.6 | 0.57 |
| Long COVID | 8 | 9 | -0.13 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.8 | 2.4 | -2 |
| ME/CFS without IBS | 2.1 | 2.4 | -0.14 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.9 | 1 | 0.9 |
| Metabolic Syndrome | 9.2 | 9.4 | -0.02 |
| Mood Disorders | 12.3 | 8.9 | 0.38 |
| multiple chemical sensitivity [MCS] | 1.7 | 0.1 | 16 |
| Multiple Sclerosis | 8.4 | 7 | 0.2 |
| Multiple system atrophy (MSA) | 1.7 | 0.7 | 1.43 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.8 | -1.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.9 | 0.9 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5.7 | 5.8 | -0.02 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12 | 9.5 | 0.26 |
| obsessive-compulsive disorder | 6.5 | 4.3 | 0.51 |
| Osteoarthritis | 2.9 | 1.7 | 0.71 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 0.7 | 0.3 | 1.33 |
| Parkinson's Disease | 9.5 | 7.3 | 0.3 |
| Polycystic ovary syndrome | 7.8 | 3.6 | 1.17 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 2.4 | 3.3 | -0.38 |
| Psoriasis | 4.1 | 4 | 0.02 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.1 | 4.7 | 0.94 |
| Rosacea | 0.6 | 1 | -0.67 |
| Schizophrenia | 7.7 | 3.6 | 1.14 |
| scoliosis | 0.6 | 1.2 | -1 |
| Sjögren syndrome | 3.2 | 3.1 | 0.03 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.2 | 0.3 | 3 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.6 | 2.17 |
| Stress / posttraumatic stress disorder | 3.4 | 3.3 | 0.03 |
| Systemic Lupus Erythematosus | 5 | 2 | 1.5 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.2 | 0.21 |
| Type 2 Diabetes | 9.9 | 9.1 | 0.09 |
| Ulcerative colitis | 5.7 | 8.8 | -0.54 |
| Unhealthy Ageing | 5.5 | 2.9 | 0.9 |
| Vitiligo | 2.5 | 2 | 0.25 |
